André P. Fay, MD, PhD Professor, PUCRS School of Medicine Chief, Medical Oncology Department – OncoclÃnicas/HSL-PUCRS Visiting Scientist at Dana-Farber Cancer Institute/ Harvard Medical School discusses
Optimal Management of Favorable Risk Clear Cell RCC Combination Therapy at the 18th International Kidney Cancer Symposium 2019, Miami, FL.
Optimal Management of Favorable Risk Clear Cell RCC Combination Therapy
